WhiteLab Genomics develops software solutions leveraging machine learning and graph knowledge technology to assist in the discovery and design of genomic therapies.

WhiteLab Genomics

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Botond Roska

Serge Picaud

Bernard Gilly

Jose Alain Sahel

Luk Vandenberghe

GenSight Biologics S.A.

Ose Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for activation and regulation of the immune system in Immuno-Oncology and Immuno-Inflammation.

Ose Immunotherapeutics

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Metric
Company Name	WhiteLab Genomics	GenSight Biologics S.A.	Ose Immunotherapeutics	Valerio Therapeutics Société anonyme
Symbol		SIGHT		ALVIO
MSH ID	COM:WHITELABGX	COM:GENSIGHT-BIOLOGICS	COM:OSE-IMMUNO	COM:VALERIOTX
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	FR	FR	FR	FR
Stage	Seed
Employee Count		16		19
Website	whitelabgx.com	gensight-biologics.com	ose-immuno.com	valeriotx.com
LinkedIn		gensight-biologics-sa
Founders

Metric
Market Cap		32.79M		16.36M
Enterprise Value
Monthly Web Traffic	2.03K		747
Web Traffic Growth	0.35		-0.61
Valuation
Raised Capital	10M

Metric
Revenue	3.17M	1.90M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.17M	1.34M
EBITDA	-33.17M	-19.62M
Operating Income	-33.17M	-20.12M
Net Income	-27.67M	-21.49M
EPS	-0.57	-0.16
Diluted EPS	-0.57	-0.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.95	0.80
Operating Profit Margin	-10.12	-9.31
EBITDA Margin	-10.47	-10.32
Net Profit Margin	-8.77	-9.15
Return on Equity	1.65	-0.87
Return on Assets	-1.34	-0.45
Return on Capital Employed	20.49	-0.67

COM:WHITELABGX

WhiteLab Genomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.65
P/B Ratio	-1.18
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	23.08	11.53
EV Multiple	-0.36	-0.14

Metric
Days Sales Outstanding
Days Payables Outstanding		2.45K
Days Inventory Outstanding	370.78	251.76
Operating Cycle	522.84	1.25K
Cash Conversion Cycle	-661.19	689.81
Asset Turnover	0.49	0.08

Metric
Operating Cash Flow	-26.44M	-19.64M
Free Cash Flow	-26.45M	-19.84M
Cash Flow to Debt	-0.74	-1.28
Operating Cash Flow/Sales	-7.37	-8.63
Free Cash Flow Yield	-1.34	-0.50

Metric
Cash & Equivalents	2.25M	7.20M
Accounts Receivable	-1.06K
Inventory		1.06
Goodwill		19.07M
Debt to Capitalization	-1.45	0.76
Debt to Assets	0.49	0.23
Current Ratio	1.57	2.88
Quick Ratio	0.69	1.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	-1.30	0.50
R&D to Revenue	7.33	5.46
SG&A to Revenue	3.10	1.83